Work

Abstract A170: Results from the phase 1 portion of a phase 1/2 study of the irreversible PI-3K inhibitor PX-866 and docetaxel.

Year: 2011

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-11-a170

Authors: Antonio Jimeno, Neil Senzer, Wen Wee Ma, Charles Rudin, Daniel Bowles, Alex Vo, Scott Peterson, Diana Hausman

Institutions: University of Colorado Cancer Center, Mary Crowley Cancer Research Center, Roswell Park Comprehensive Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2146634767

Cites:

Cited by: 1

Related to: 10